Halozyme Therapeutics, Inc. (LON:0J2O)
63.16
+1.48 (2.41%)
At close: Aug 8, 2025
ANSYS Revenue
Halozyme Therapeutics had revenue of $325.72M USD in the quarter ending June 30, 2025, with 40.79% growth. This brings the company's revenue in the last twelve months to $1.18B, up 34.97% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+34.97%
P/S Ratio
6.36
Revenue / Employee
$3.37M
Employees
350
Market Cap
5.47B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
Oxford Nanopore Technologies | 183.19M |
HUTCHMED (China) | 439.54M |
Halozyme Therapeutics News
- 18 days ago - European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - PRNewsWire
- 19 days ago - Halozyme to Report Second Quarter 2025 Financial and Operating Results - PRNewsWire
- 27 days ago - Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) - Seeking Alpha
- 5 weeks ago - Halozyme Therapeutics Added to Russell 1000® Index - PRNewsWire
- 7 weeks ago - Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire
- 2 months ago - Halozyme Therapeutics: The Waters Become Muddled - Seeking Alpha
- 2 months ago - Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
- 2 months ago - Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga